文献速递儿科与产科急症消化、代谢与肾脏急症

Brexanolone注射液治疗产后抑郁症:两项多中心、双盲、随机、安慰剂对照的3期试验

Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
PubMed 文献 · Lancet · 2018-08-31
一句话结论两项3期试验显示,brexanolone注射液(90 μg/kg/h或60 μg/kg/h,静脉输注60 h)较安慰剂显著降低产后抑郁症患者HAM-D总分,起效快且疗效持续至研究期间。

两项在美国30个临床研究中心和精神科专科单位进行的多中心、双盲、随机、安慰剂对照3期试验,纳入产后6个月内的产后抑郁症女性(研究1 HAM-D≥26分,研究2 HAM-D 20-25分),分别随机接受brexanolone 90 μg/kg/h、60 μg/kg/h或安慰剂静脉输注60 h(研究1),或brexanolone 90 μg/kg/h或安慰剂静脉输注60 h(研究2)。主要终点为60 h时HAM-D总分较基线的变化。研究1中BRX60组和BRX90组HAM-D总分降低均显著大于安慰剂组,研究2中BRX90组也显著大于安慰剂组。常见不良事件为头痛、头晕和嗜睡。作者认为brexanolone注射液是产后抑郁症的新型治疗药物,有潜力改善治疗选择。

要点

  • 研究1中,60 h时HAM-D总分较基线降低:BRX60组19.5分、BRX90组17.7分 vs 安慰剂组14.0分(BRX60组差异-5.5,95%CI -8.8至-2.2,p=0.0013;BRX90组差异-3.7,95%CI -6.9至-0.5,p=0.0252)。
  • 研究2中,60 h时HAM-D总分较基线降低:BRX90组14.6分 vs 安慰剂组12.1分(差异-2.5,95%CI -4.5至-0.5,p=0.0160)。
  • Brexanolone组最常见治疗中出现的不良事件为头痛、头晕和嗜睡。
  • 研究2中BRX90组1例患者发生2起严重不良事件(意识状态改变和晕厥),被认为与治疗相关。
  • 研究1中BRX60组1例患者在随访期间发生2起严重不良事件(自杀意念和故意过量服药企图)。

适用人群与场景

  • 年龄18-45岁、筛查时产后6个月或以内的产后抑郁症女性,研究1要求HAM-D 17项评分≥26分,研究2要求20-25分。
  • 排除需要透析的肾衰竭、贫血、已知对allopregnanolone或黄体酮过敏、有精神分裂症/双相障碍/分裂情感性障碍病史的女性。

诊断标准与关键阈值

  • 产后抑郁症诊断,研究1入选标准为17项HAM-D评分≥26分,研究2为20-25分。

处置流程与药物剂量

  • 研究1:随机(1:1:1)接受brexanolone 90 μg/kg/h(BRX90)、brexanolone 60 μg/kg/h(BRX60)或匹配安慰剂,单次静脉输注60 h。
  • 研究2:随机(1:1)接受brexanolone 90 μg/kg/h(BRX90)或匹配安慰剂,单次静脉输注60 h。
  • 随访至第30天。

研究设计与关键结果

  • 两项双盲、随机、安慰剂对照3期试验,在美国30个临床研究中心和精神科专科单位进行;研究1随机138例(BRX90 n=45,BRX60 n=47,安慰剂 n=46),研究2随机108例(BRX90 n=54,安慰剂 n=54)。
  • 研究1主要终点:60 h时HAM-D总分较基线最小二乘均值降低BRX60组19.5分(SE 1.2)、BRX90组17.7分(SE 1.2) vs 安慰剂组14.0分(SE 1.1);BRX60组差异-5.5(95%CI -8.8至-2.2,p=0.0013),BRX90组差异-3.7(95%CI -6.9至-0.5,p=0.0252)。
  • 研究2主要终点:60 h时HAM-D总分较基线最小二乘均值降低BRX90组14.6分(SE 0.8) vs 安慰剂组12.1分(SE 0.8);差异-2.5(95%CI -4.5至-0.5,p=0.0160)。
  • 研究1不良事件:BRX60组19例、BRX90组22例 vs 安慰剂组22例;研究2:BRX90组25例 vs 安慰剂组24例。
  • 最常见治疗中出现的不良事件为头痛(研究1:BRX60组7例、BRX90组6例 vs 安慰剂组7例;研究2:BRX90组9例 vs 安慰剂组6例)、头晕(研究1:BRX60组6例、BRX90组6例 vs 安慰剂组1例;研究2:BRX90组5例 vs 安慰剂组4例)和嗜睡(研究1:BRX60组7例、BRX90组2例 vs 安慰剂组3例;研究2:BRX90组4例 vs 安慰剂组2例)。
  • 研究1中BRX60组1例患者发生2起严重不良事件(自杀意念和故意过量服药企图,发生于随访期间);研究2中BRX90组1例患者发生2起严重不良事件(意识状态改变和晕厥),被认为与治疗相关。

证据类型、等级与局限

  • 证据类型:两项多中心、双盲、随机、安慰剂对照3期试验。
  • 作者结论:brexanolone注射液治疗产后抑郁症在60 h时较安慰剂显著且临床有意义地降低HAM-D总分,起效快且研究期间疗效持续;结果提示brexanolone注射液是产后抑郁症的新型治疗药物,有潜力改善该障碍女性的治疗选择。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为brexanolone注射液是产后抑郁症的新型治疗药物,有潜力改善该障碍女性的治疗选择。
  • 对于产后6个月以内、HAM-D评分符合研究入选标准(研究1≥26分,研究2 20-25分)的产后抑郁症女性,brexanolone 90 μg/kg/h或60 μg/kg/h静脉输注60 h较安慰剂显著降低60 h时HAM-D总分。
  • 用药期间需监测头痛、头晕和嗜睡等不良事件;研究2中BRX90组有1例发生与治疗相关的严重不良事件(意识状态改变和晕厥)。

指南或共识出处

  • Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials(Lancet);试验注册号NCT02942004(研究1)和NCT02942017(研究2)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Post-partum depression is associated with substantial morbidity, and improved pharmacological treatment options are urgently needed. We assessed brexanolone injection (formerly SAGE-547 injection), a positive allosteric modulator of γ-aminobutyric-acid type A (GABAA) receptors, for the treatment of moderate to severe post-partum depression.

METHODS: We did two double-blind, randomised, placebo-controlled, phase 3 trials, at 30 clinical research centres and specialised psychiatric units in the USA. Eligible women were aged 18-45 years, 6 months post partum or less at screening, with post-partum depression and a qualifying 17-item Hamilton Rating Scale for Depression (HAM-D) score (≥26 for study 1; 20-25 for study 2). Women with renal failure requiring dialysis, anaemia, known allergy to allopregnanolone or to progesterone, or medical history of schizophrenia, bipolar disorder, or schizoaffective disorder were excluded. Patients were randomly assigned (1:1:1) to receive a single intravenous injection of either brexanolone 90 μg/kg per h (BRX90), brexanolone 60 μg/kg per h (BRX60), or matching placebo for 60 h in study 1, or (1:1) BRX90 or matching placebo for 60 h in study 2. Patients, the study team, site staff, and the principal investigator were masked to treatment allocation. The primary efficacy endpoint was the change from baseline in the 17-item HAM-D total score at 60 h, assessed in all patients who started infusion of study drug or placebo, had a valid HAM-D baseline assessment, and had at least one post-baseline HAM-D assessment. The safety population included all randomised patients who started infusion of study drug or placebo. Patients were followed up until day 30. The trials have been completed and are registered with ClinicalTrials.gov, numbers NCT02942004 (study 1) and NCT02942017 (study 2).

FINDINGS: Participants were enrolled between Aug 1, 2016, and Oct 19, 2017, in study 1, and between July 25, 2016, and Oct 11, 2017, in study 2. We screened 375 women simultaneously across both studies, of whom 138 were randomly assigned to receive either BRX90 (n=45), BRX60 (n=47), or placebo (n=46) in study 1, and 108 were randomly assigned to receive BRX90 (n=54) or placebo (n=54) in study 2. In study 1, at 60 h, the least-squares (LS) mean reduction in HAM-D total score from baseline was 19·5 points (SE 1·2) in the BRX60 group and 17·7 points (1·2) in the BRX90 group compared with 14·0 points (1·1) in the placebo group (difference -5·5 [95% CI -8·8 to -2·2], p=0·0013 for the BRX60 group; -3·7 [95% CI -6·9 to -0·5], p=0·0252 for the BRX90 group). In study 2, at 60 h, the LS mean reduction in HAM-D total score from baseline was 14·6 points (SE 0·8) in the BRX90 group compared with 12·1 points (SE 0·8) for the placebo group (difference -2·5 [95% CI -4·5 to -0·5], p=0·0160). In study 1, 19 patients in the BRX60 group and 22 patients in the BRX90 group had adverse events compared with 22 patients in the placebo group. In study 2, 25 patients in the BRX90 group had adverse events compared with 24 patients in the placebo group. The most common treatment-emergent adverse events in the brexanolone groups were headache (n=7 BRX60 group and n=6 BRX90 group vs n=7 placebo group for study 1; n=9 BRX90 group vs n=6 placebo group for study 2), dizziness (n=6 BRX60 group and n=6 BRX90 group vs n=1 placebo group for study 1; n=5 BRX90 group vs n=4 placebo group for study 2), and somnolence (n=7 BRX60 group and n=2 BRX90 group vs n=3 placebo group for study 1; n=4 BRX90 group vs n=2 placebo group for study 2). In study 1, one patient in the BRX60 group had two serious adverse events (suicidal ideation and intentional overdose attempt during follow-up). In study 2, one patient in the BRX90 group had two serious adverse events (altered state of consciousness and syncope), which were considered to be treatment related.

INTERPRETATION: Administration of brexanolone injection for post-partum depression resulted in significant and clinically meaningful reductions in HAM-D total score at 60 h compared with placebo, with rapid onset of action and durable treatment response during the study period. Our results suggest that brexanolone injection is a novel therapeutic drug for post-partum depression that has the potential to improve treatment options for women with this disorder.

FUNDING: Sage Therapeutics, Inc.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet. 2018. PMID: 30177236. doi:10.1016/S0140-6736(18)31551-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。